CD Antigen Cancer Therapy Market
CD Antigen Cancer Therapy Market - Global Industry Assessment & Forecast
#
Pages:
197
Base Year:
2023
Jun - 2024
Format:
Report Code:
VMR-2503
Segments Covered
By
Type of CD Antigen Targeted CD19, CD20, CD30, CD33, CD38, CD70, Other Types
-
By
Therapy Type Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cell Therapy, Bi-specific T-cell Engagers (BiTEs), Radioimmunotherapy, Immunotoxins
-
By
Cancer Type Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Lung Cancer, Prostate Cancer, Other Cancer Types
-
By
End User Hospitals, Specialty Clinics, Cancer Treatment Centers, Research Institutes
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD 26.6 Billion |
 Revenue 2032:
|
USD 45.29 Billion |
 Revenue CAGR
(2024 - 2032): |
6.1% |
Fastest Growing Region (2024 -
2032)
|
Asia Pacific |
Largest Region (2023):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
CD Antigen Cancer Therapy Market Segment Analysis
- CD Antigen Cancer Therapy Type of CD Antigen Targeted Outlook (Revenue, USD Million, 2018 - 2030)
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- CD Antigen Cancer Therapy Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- CD Antigen Cancer Therapy Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- CD Antigen Cancer Therapy End User Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
-
North America CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
-
North America CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
-
North America CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- U.S.
- U.S. CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- U.S. CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- U.S. CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- U.S. CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- U.S. CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- Canada
- Canada CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Canada CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Canada CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Canada CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Canada CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Mexico
- Mexico CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Mexico CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Mexico CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Mexico CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Mexico CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
North America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- Europe
-
Europe CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
-
Europe CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
-
Europe CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
-
Europe CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- U. K.
- U.K. CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- U.K. CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- U.K. CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- U.K. CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- U.K. CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- France
- France CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- France CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- France CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- France CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- France CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Germany
- Germany CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Germany CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Germany CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Germany CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Germany CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Italy
- Italy CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Italy CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Italy CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Italy CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Italy CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Spain
- Spain CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Spain CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Spain CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Spain CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Spain CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Rest of Europe
- Rest of Europe CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Rest of Europe CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Rest of Europe CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Rest of Europe CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Rest of Europe CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Europe CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- Asia Pacific
-
Asia Pacific CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
-
Asia Pacific CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
-
Asia Pacific CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
-
Asia Pacific CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- China
- China CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- China CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- China CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- China CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- China CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- Japan
- Japan CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Japan CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Japan CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Japan CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Japan CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Germany
- Germany CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Germany CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Germany CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Germany CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Germany CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
India
- India CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- India CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- India CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- India CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- India CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
South Korea
- South Korea CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- South Korea CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- South Korea CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- South Korea CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- South Korea CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
South East Asia
- South East Asia CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- South East Asia CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- South East Asia CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- South East Asia CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- South East Asia CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Rest of Asia Pacific
- Rest of Asia Pacific CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Rest of Asia Pacific CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Rest of Asia Pacific CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Rest of Asia Pacific CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Rest of Asia Pacific CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Asia Pacific CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- Latin America
-
Latin America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
-
Latin America CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
-
Latin America CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
-
Latin America CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Brazil
- Brazil CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Brazil CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Brazil CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Brazil CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Brazil CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- Argentina
- Argentina CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Argentina CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Argentina CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Argentina CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Argentina CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Rest of Latin America
- Rest of Latin America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Rest of Latin America CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Rest of Latin America CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Rest of Latin America CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Rest of Latin America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Latin America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- Middle East & Africa
-
Middle East & Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
-
Middle East & Africa CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
-
Middle East & Africa CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
-
Middle East & Africa CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- GCC Countries
- GCC Countries CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- GCC Countries CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- GCC Countries CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- GCC Countries CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- GCC Countries CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- South Africa
- South Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- South Africa CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- South Africa CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- South Africa CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- South Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Rest of Middle East & Africa
- Rest of Middle East & Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Other Types
- Rest of Middle East & Africa CD Antigen Cancer Therapy Market, by Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
- Rest of Middle East & Africa CD Antigen Cancer Therapy Market, by Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- Rest of Middle East & Africa CD Antigen Cancer Therapy Market, by End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
- Rest of Middle East & Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
-
Middle East & Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
- North America
Vantage Market
Research | 25-Jun-2024
FAQ
Frequently Asked Question
What is the global demand for CD Antigen Cancer Therapy in terms of revenue?
-
The global CD Antigen Cancer Therapy valued at USD 26.6 Billion in 2023 and is expected to reach USD 45.29 Billion in 2032 growing at a CAGR of 6.1%.
Which are the prominent players in the market?
-
The prominent players in the market are Merck & Co. Inc. (U.S.), Johnson & Johnson Inc. (U.S.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Roche Holdings AG (Switzerland), Bristol Myers Squibb Company (U.S.), Biogen Inc. (U.S.), Celgene Corp. (U.S.), Genmab A/S (Denmark), Immunomedics Inc. (U.S.), Gilead Sciences Inc. (U.S.), AstraZeneca PLC (UK), Takeda Pharmaceutical Company Ltd. (Japan), Seattle Genetics Inc. (U.S.).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 6.1% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the CD Antigen Cancer Therapy include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the CD Antigen Cancer Therapy in 2023.
